Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues

Best Practice and Research: Clinical Gastroenterology

Volumn 22, Issue 6, 2008, Pages 1093-1108

  Buster, Erik H C J ^a   Schalm, Solko W ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

adefovir; entecavir; lamivudine; pegylated interferon; sustained response; telbivudine; tenofovir

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR;

AGITATION; ALOPECIA; ANOREXIA; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEARING LOSS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; INDUCED HYPOTHERMIA; INJECTION SITE ERYTHEMA; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LONG TERM CARE; MENTAL INSTABILITY; MONOTHERAPY; MYALGIA; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; POLYNEUROPATHY; PRACTICE GUIDELINE; RETINOPATHY; SEIZURE; SEROCONVERSION; SIDE EFFECT; SJOEGREN SYNDROME; SUICIDAL IDEATION; TASTE DISORDER; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT DURATION; VIRUS GENE;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LAMIVUDINE; NUCLEOSIDES; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 59249095799     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2008.11.007     Document Type: Article

References (104)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 2 (2004) 97-107
2. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 24 (1997) 1733-1745
3. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin Liver Dis 25 suppl 1 (2005) 3-8
4. de Franchis R., Hadengue A., Lau G., et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 39 suppl 1 (2003) S3-S25
5. Cooksley W.G., Piratvisuth T., Lee S.D., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 4 (2003) 298-305
6. Cornberg M., Protzer U., Dollinger M.M., et al. The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat 15 suppl 1 (2008) 1-21
7. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. Hepatol Int (2008) 10.1007/s12072-008-9080-3
8. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 2 (2007) 507-539
9. Buster E.H., van Erpecum K.J., Schalm S.W., et al. Treatment of chronic hepatitis B virus infection-Dutch national guidelines. Neth J Med 66 7 (2008) 292-306
10. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 15 (2004) 1521-1531
11. van Zonneveld M., Honkoop P., Hansen B.E., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 3 (2004) 804-810
12. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 5 (1997) 1660-1667
13. Lin S.M., Sheen I.S., Chien R.N., et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 3 (1999) 971-975
14. Buster E.H., Flink H.J., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology 135 2 (2008) 459-467
15. Haria M., and Benfield P. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 50 5 (1995) 873-896
16. Korenman J., Baker B., Waggoner J., et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114 8 (1991) 629-634
17. Hoofnagle J.H., Peters M., Mullen K.D., et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95 5 (1988) 1318-1325
18. Perrillo R.P., Schiff E.R., Davis G.L., et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323 5 (1990) 295-301
19. Janssen H.L., Gerken G., Carreno V., et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30 1 (1999) 238-243
20. Wong D.K., Cheung A.M., O'Rourke K., et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119 4 (1993) 312-323
21. Janssen H.L., Berk L., Schalm S.W., et al. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. Gut 33 8 (1992) 1094-1098
22. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 5 6 (1998) 389-397
23. Janssen H.L., van Zonneveld M., and Schalm S.W. Hepatitis B. N Engl J Med 350 26 (2004) 2719-2720
24. Lampertico P., Del Ninno E., Manzin A., et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26 6 (1997) 1621-1625
25. Hadziyannis S., Bramou T., Makris A., et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 11 suppl 1 (1990) S133-S136
26. Pastore G., Santantonio T., Milella M., et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 14 2-3 (1992) 221-225
27. Fattovich G., Farci P., Rugge M., et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 15 4 (1992) 584-589
28. Lok A.S., Heathcote E.J., and Hoofnagle J.H. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 120 7 (2001) 1828-1853
29. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 22 (1996) 1422-1427
30. Lin S.M., Tai D.I., Chien R.N., et al. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 11 4 (2004) 349-357
31. Craxi A., and Cooksley W.G. Pegylated interferons for chronic hepatitis B. Antiviral Res 60 2 (2003) 87-89
32. Kozlowski A., Charles S.A., and Harris J.M. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15 7 (2001) 419-429
33. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
34. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 13 (2002) 975-982
35. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 9454 (2005) 123-129
36. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 26 (2005) 2682-2695
37. Zhao H., Si C.W., Wei L., et al. A multicenter, randomized, open-label study of peginterferon alfa-2b vs interferon alfa-2b for the treatment of Chinese patients with HBeAg+ve chronic hepatitis B. J Hepatol 44 suppl 2 (2006) S20-S21
38. Gish R.G., Lau D.T., Schmid P., and Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 102 12 (2007) 2718-2723
39. Janssen H.L., Brouwer J.T., Nevens F., et al. Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). BMJ 306 6870 (1993) 107-108
40. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 8 (1973) 646-649
41. van Zonneveld M., Flink H.J., Verhey E., et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 21 9 (2005) 1163-1171
42. Janssen H.L., Berk L., Vermeulen M., and Schalm S.W. Seizures associated with low-dose alpha-interferon. Lancet 336 8730 (1990) 1580
43. Buster E.H., Hansen B.E., Buti M., et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 46 2 (2007) 388-394
44. Flink H.J., Sprengers D., Hansen B.E., et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 54 11 (2005) 1604-1609
45. Hoofnagle J.H., Di Bisceglie A.M., et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104 4 (1993) 1116-1121
46. Perrillo R., Tamburro C., Regenstein F., et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 109 3 (1995) 908-916
47. Chan H.L., Leung N.W., Hui A.Y., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 4 (2005) 240-250
48. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 12 (2004) 1206-1217
49. Flink H.J., van Zonneveld M., Hansen B.E., et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 2 (2006) 297-303
50. ®). J Hepatol 42 suppl 2 (2005) S178
51. ®) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol 42 suppl 2 (2005) S30
52. ®) alone or in combination with lamivudine vs lamivudine alone. Hepatology 40 S4 (2004) A1142
53. Craxi A., Di Bona D., and Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 39 suppl 1 (2003) S99-S105
54. Bonino F., Marcellin P., Lau G.K., et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 5 (2007) 699-705
55. van Nunen A.B., Hansen B.E., Suh D.J., et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52 3 (2003) 420-424
56. Dienstag J.L., Cianciara J., Karayalcin S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37 4 (2003) 748-755
57. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 26 (2005) 2673-2681
58. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 9 (2003) 800-807
59. Santantonio T., Mazzola M., Iacovazzi T., et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32 2 (2000) 300-306
60. Chien R.N., Yeh C.T., Tsai S.L., et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 5 (2003) 1267-1273
61. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 25 (2007) 2576-2588
62. Poynard T., Hou J.L., Chutaputti A., et al. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine. J Hepatol 48 suppl 2 (2008) S263-S2S4
63. Buster E.H., Flink H.J., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Hepatology 46 suppl 1 (2007) 667A
64. Marcellin P., Piratvisuth T., Brunetto M.R., et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) with or without lamivudine: results of 4-year follow-up. J Hepatol 48 suppl 2 (2008) S46
65. Arauz-Ruiz P., Norder H., Robertson B.H., et al. A new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 83 8 (2002) 2059-2073
66. Fung S.K., and Lok A.S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?. Hepatology 40 4 (2004) 790-792
67. Stuyver L., De Gendt S., Van Geyt C., et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 81 1 (2000) 67-74
68. Sumi H., Yokosuka O., Seki N., et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37 1 (2003) 19-26
69. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 3 (2000) 554-559
70. Chu C.J., Hussain M., and Lok A.S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122 7 (2002) 1756-1762
71. Buti M., Cotrina M., Valdes A., et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?. J Hepatol 36 3 (2002) 445-446
72. Lurie Y., Manns M.P., Gish R.G., et al. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B. J Hepatol 42 suppl 2 (2005) 184
73. Yuen M.F., Wong D.K., Sablon E., et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 8 6 (2003) 531-534
74. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 10 (2006) 1001-1010
75. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 9 (2003) 808-816
76. Lau G.K., Piratvisuth T., Luo K.X., et al. Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 44 suppl 2 (2006) S23
77. ®] sustain responses 2 years post-treatment. J Hepatol 44 suppl 2 (2006) S275
78. Leung N.W., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 6 (2001) 1527-1532
79. Song B.C., Suh D.J., Lee H.C., et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 4 Pt 1 (2000) 803-806
80. Chang T.T., Lai C.L., Chien R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 11 (2004) 1276-1282
81. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 6 (2006) 1656-1665
82. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 6 (2006) 1743-1751
83. Ryu S.H., Chung Y.H., Choi M.H., et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 39 4 (2003) 614-619
84. Wai C.T., Chu C.J., Hussain M., and Lok A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36 6 (2002) 1425-1430
85. Zoulim F., and Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 48 suppl 1 (2008) S2-S19
86. Fattovich G., Giustina G., Favarato S., and Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24 1 (1996) 38-47
87. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36 5 suppl 1 (2002) S237-S244
88. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 9 (2006) 1350-1359
89. Lok A.S., Wu P.C., Lai C.L., et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102 6 (1992) 2091-2097
90. Manesis E.K., and Hadziyannis S.J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121 1 (2001) 101-109
91. Chan H.L., Hui A.Y., Wong V.W., et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 41 6 (2005) 1357-1364
92. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 17 (1999) 1256-1263
93. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 2 (1998) 61-68
94. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 1 (2000) 172-180
95. Schalm S.W., Heathcote J., Cianciara J., et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46 4 (2000) 562-568
96. Schiff E.R., Dienstag J.L., Karayalcin S., et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 38 6 (2003) 818-826
97. Buti M., Cotrina M., Jardi R., et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 8 4 (2001) 270-275
98. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 4 Pt 1 (2000) 847-851
99. Lee Y.S., Suh D.J., Lim Y.S., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 6 (2006) 1385-1391
100. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 10 (2006) 1011-1020
101. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 7 (2006) 2039-2049
102. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 4 (2005) 1198-1209
103. Heathcote E.J., Gane E., de Man R.A., et al. A randomized, double-bind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. Hepatology 46 4, suppl 1 (2007) 861A
104. Marcellin P., Buti M., Krastev Z., et al. A randomised, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. Hepatology 46 4 suppl 1 (2007) 290A-291A